Phenobarbital versus benzodiazepines in alcohol withdrawal syndrome
Neuropsychopharmacology Reports · 2023
DOI: 10.1002/npr2.12347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychopharmacology Reports, 2023. Verfasst von Deanna Malone und 5 weiteren Autor:innen. Beteiligte Einrichtung: Duke Regional Hospital, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Substance Withdrawal Syndrome, Alcoholism. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aim
Phenobarbital, a long‐acting barbiturate, presents an alternative to conventional benzodiazepine treatment for alcohol withdrawal syndrome (AWS). Currently, existing research offers only modest guidance on the safety and effectiveness of phenobarbital in managing AWS in hospital settings. The study objective was to assess if a phenobarbital protocol for the treatment of AWS reduces respiratory complications when compared to a more traditionally used benzodiazepine protocol.
Methods
A retrospective cohort study analyzing adults who received either phenobarbital or benzodiazepine‐based treatment for AWS over a 4‐year period, 2015–2019, in a community teaching hospital in a large academic medical system.
Results
A total of 147 patient encounters were included (76 phenobarbital and 71 benzodiazepine). Phenobarbital was associated with a significantly decreased risk of respiratory complications, defined by the occurrence of intubation (15/76 phenobarbital [20%] vs. 36/71 benzodiazepine [51%]) and decreased incidence of the requirement of six or greater liters of oxygen when compared with benzodiazepines (10/76 [13%] vs. 28/71 [39%]). There was a significantly higher incidence of pneumonia in benzodiazepine patients (15/76 [20%] vs. 33/71 [47%]). Mode Richmond Agitation Sedation Scale (RASS) scores were more frequently at goal (0 to −1) between 9 and 48 h after the loading dose of study medication for phenobarbital patients. Median hospital and ICU length of stay were significantly shorter for phenobarbital patients when compared with benzodiazepine patients (5 vs. 10 days and 2 vs. 4 days, respectively).
Conclusion
Parenteral phenobarbital loading doses with an oral phenobarbital tapered protocol for AWS resulted in decreased risk of respiratory complications when compared to standard treatment with benzodiazepines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke Regional Hospital, Durham, North Carolina, USA.
- Duke University Hospital, Durham, North Carolina, USA.
- Duke University School of Nursing, Durham, North Carolina, USA.
- Durham Veterans Health Administration, Durham, North Carolina, USA.
ORCID-Profile: Deanna Malone, Blair N Costin
Zitieren
APA
Malone, D., Costin, B. N., MacElroy, D., Al-Hegelan, M., Thompson, J., & Bronshteyn, Y. (2023). Phenobarbital versus benzodiazepines in alcohol withdrawal syndrome. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12347
Vancouver
Malone D, Costin BN, MacElroy D, Al-Hegelan M, Thompson J, Bronshteyn Y. Phenobarbital versus benzodiazepines in alcohol withdrawal syndrome. Neuropsychopharmacology Reports. 2023. doi:10.1002/npr2.12347
BibTeX
@article{Malone2023,
author = {Malone, Deanna and Costin, Blair N and MacElroy, Dawn and Al-Hegelan, Mashael and Thompson, Julie and Bronshteyn, Yuriy},
title = {Phenobarbital versus benzodiazepines in alcohol withdrawal syndrome},
journal = {Neuropsychopharmacology Reports},
year = {2023},
doi = {10.1002/npr2.12347}
}
EUVIMED